Kollidon® 12 PF / Kollidon® 17 PF

The endotoxin-controlled PVP-based solubilizers for parenteral and oral formulations

Did you know that Kollidon® 12 PF and Kollidon® 17 PF are highly suitable for injectable formulations?

Kollidon® 12 PF/ Kollidon® 17 PF low molecular weight make them particularly suitable for parenteral applications. Additionally, they are used as matrix formers in solid dispersions, highly effective stabilizers in liquid dispersions, as well as functional pore formers in solid oral dosage forms.

- ✓ Highly soluble low molecular weight povidone
- ✓ Endotoxin-controlled
- ✓ Suitable as solubilizer and crystallization inhibitor
- ✓ PeroXeal™ packaging for minimizing peroxide formation

BASF
We create chemistry

Pharma Solutions. Focusing on your needs with platform solutions.

Follow us on Twitter: BASF_Pharma | www.pharma.basf.com

Product Benefits

- Formation of water-soluble complexes with APIs inhibits crystallization
- Excellent lyophilization agents and suspension stabilizers
- Rapid renal elimination without polymer accumulation in the body due to low molecular weight
- Proven tolerability
- Endotoxin-controlled
- Complies to the Povidone monographs of Ph.Eur., USP-NF, and JP
- FDA IID listed
- Innovative PeroXeal™ packaging concept limiting peroxide formation – a unique combination of an oxygen impermeable inliner packaging and a filling process under inert conditions

Product Details

Brand/Trade name	Kollidon® 12 PF	Kollidon® 17 PF
Generic name	Povidon(e), polyvidone, soluble polyvinylpyrrolidone, PVP	
CAS number	9003-39-8	
PRD number	30034972	30034981
Packaging size	50 kg plastic drum with inliner	50 kg plastic drum with inliner
Article number	50444166	50029276
Manufacturing site	Ludwigshafen (Germany)	
Physical form	Powder	

Regulatory Documentation

A Certificate of Suitability of Monographs of the European Pharmacopoeia (CEP) is available (CEP-2007-077).

Pharmacopoeia Monographs and Titles

Kollidon® 12 PF and Kollidon® 17 PF meet the requirements of the current monograph “Povidone” in the European Pharmacopoeia, United States Pharmacopeia, and Japanese Pharmacopoeia.

Preclinical Safety Data

Tox Abstract (summary of the design and results of the pre-clinical studies performed) is available.

For further information on the preclinical safety data and our secrecy agreement please contact your sales representative.

Get your sample today!
pharma.solutions@basf.com

 03_180301e-00